Smith+Nephew to Host Capital Markets Days; Strategy Update in Dec 2025

Smith+Nephew will host Capital Markets Days in London and New York on 8 December 2025 and 11 December 2025 respectively.

Rhea-AI Filing Summary

Smith+Nephew will host Capital Markets Days in London and New York on 8 December 2025 and 11 December 2025 respectively. The London session (Royal College of Surgeons) will introduce the company’s new strategy following the conclusion of its 12-Point Plan, including mid-term priorities and financial goals. The New York session (New York Stock Exchange) will present further detail on the portfolio that management expects will drive the next growth phase, with customer and Key Opinion Leader input. Both events will be led by Chief Executive Officer Deepak Nath and Chief Financial Officer John Rogers with other Executive Committee members; attendance requires pre-registration and sessions will be webcast. The company reported annual sales of $5.8 billion in 2024 in the background information provided.

Positive

• Formal strategy update planned to follow the 12-Point Plan, providing clarity on mid-term priorities
• Senior management engagement with CEO and CFO presenting increases transparency for investors
• Dual-location events (London and New York) plus webcasts broaden investor access
• Background scale metric: reported $5.8 billion in annual sales for 2024

Negative

• No specific financial targets or numeric mid-term goals were disclosed in this notice
• Forward-looking disclaimers note many risks (geopolitical, regulatory, supply chain) which could affect outcomes
• In-person attendance requires pre-registration, potentially limiting direct access for some investors

Insights

Investor Relations Strategist

Capital Markets Days signal a formal strategy relaunch and investor outreach.

The events provide a structured forum to present the post-12-Point Plan strategy, mid-term priorities and financial targets directly to institutional investors and analysts. Senior management participation (CEO Deepak Nath and CFO John Rogers) increases the events' credibility and gives markets a single narrative on future plans.

Risks include limited new data at the events and broad forward-looking disclaimers; investors should use the webcasts and published presentations to capture concrete metrics and timelines presented on 8 December 2025 and 11 December 2025.

Corporate Finance Analyst

A focused presentation of mid-term financial goals could affect guidance expectations and valuation.

If the company discloses specific mid-term financial goals or targets, that information can materially affect investor models given reported 2024 sales of $5.8 billion. The New York session’s deeper portfolio detail may clarify growth drivers across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Absent concrete numeric targets in this notice, the material change will depend on whether management publishes quantifiable revenue, margin or cost metrics during the December events; attendees should watch for any disclosed targets or timeline references at those sessions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What dates will Smith+Nephew (SNN) hold its Capital Markets Days?

The London event is on 8 December 2025 and the New York event is on 11 December 2025.

Who will present at the Smith+Nephew (SNN) Capital Markets Days?

Presentations will be led by CEO Deepak Nath and CFO John Rogers with members of the Executive Committee.

Will Smith+Nephew (SNN) provide webcasts or materials for the events?

Yes, both sessions will be webcast and the presentations will be made available via the company website.

What strategic topics will Smith+Nephew (SNN) cover at the Capital Markets Days?

The London event will introduce the new strategy after the 12-Point Plan and mid-term priorities; the New York event will give greater detail on the portfolio driving the next growth phase.

Does the notice include recent financial figures for Smith+Nephew (SNN)?

Yes, the background states the Group generated annual sales of $5.8 billion in 2024.

How can investors register to attend Smith+Nephew (SNN) events?

In-person attendance requires pre-registration via the company’s investor website at https://www.smith-nephew.com/en/about-us/investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/08/2025 - 06:51 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the

Securities Exchange Act of 1934

October 08, 2025

Commission File Number 001-14978

SMITH & NEPHEW plc

(Registrant’s name)

Building 5, Croxley Park, Hatters Lane

Watford, England, WD18 8YE

 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ✔         Form 40-F __

Smith+Nephew Announces Capital Markets Days in London and New York

8 October 2025

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces that it will host Capital Markets Days for institutional investors and financial analysts in London and New York on Monday 8 and Thursday 11 December 2025 respectively.

​The London event will introduce Smith+Nephew's new strategy following the conclusion of the 12-Point Plan, including mid-term priorities and financial goals. This will be held at The Royal College of Surgeons from 1pm to 5pm GMT / 8am to 12pm EST on 8 December.

​The New York event will provide greater detail on Smith+Nephew's innovative portfolio that will drive the next phase of growth, with insight from Smith+Nephew customers and Key Opinion Leaders. This event will be held at the New York Stock Exchange from 2pm to 6pm GMT / 9am to 1pm EST on 11 December.

​Both events will be led by Chief Executive Officer Deepak Nath, accompanied by Chief Financial Officer John Rogers and members of the Executive Committee. Further information will be provided in due course, and participants are encouraged to attend both events, either in person or virtually.

​In person attendance at these events requires pre-registration. Investors and analysts should register via Smith+Nephew's website at https://www.smith-nephew.com/en/about-us/investors.

​The sessions will also be webcast and the presentations made available via the website.

Enquiries

Investors/ Analysts

Emily Heaven / Cora McCallum               +44 (0) 1923 477433

Smith+Nephew

Media

Charles Reynolds                                       +44 (0) 1923 477314

Smith+Nephew

​About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

​Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

​For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Smith & Nephew plc
		(Registrant)
Date: October 08, 2025	By:	/s/ Helen Barraclough
		Helen Barraclough
		Company Secretary